ライフサイエンスコーパス: nasal congestion

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 st agents are not very effective in treating nasal congestion.

2 il counts and lung function and increases in nasal congestion.

3 th 35.3% in subjects without both asthma and nasal congestion.

4 sophageal reflux disease, and 54 percent had nasal congestion.

5 The most common adverse events were nasal congestion (16% of patients) and myalgia (14%).

6 most often within 5 days of inoculation were nasal congestion (36%), headache (30%), and sore throat

7 oarseness (2.0 days and 3.0 days; P = 0.02), nasal congestion (4.0 days and 6.0 days; P = 0.002), nas

8 ring exacerbations: 73% had lacrimation, 51% nasal congestion, 46% conjunctival injection and 40% pto

9 In the subgroup reporting both asthma and nasal congestion, 55.8% had insomnia symptoms compared w

10 RSV was more commonly associated with nasal congestion (68% vs. 55%; P=.03), wheezing by histo

11 ress (82%), chronic cough (99%), and chronic nasal congestion (97%).

12 frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was signif

13 As expected, nasal congestion and rhinorrhea were most common, but in

14 Some also present with nasal congestion and subjective olfactory impairment.

15 al cytokine levels, nasal secretion weights, nasal congestion and symptom scores were determined.

16 respiratory distress in >80% of cases, daily nasal congestion and wet cough starting soon after birth

17 9 years (vs 50-64 years), symptoms of cough, nasal congestion and wheezing, and longer interval from

18 y group included peripheral edema, headache, nasal congestion, and anemia.

19 de overweight and obesity, alcohol, smoking, nasal congestion, and estrogen depletion in menopause.

20 exposure to seasonal pollen causes itching, nasal congestion, and repeated sneezing, with profound e

21 Initial symptoms included fever, cough, nasal congestion, and sore throat.

22 the reslizumab groups were headache, cough, nasal congestion, and upper respiratory tract infection.

23 had a beneficial effect on airway symptoms (nasal congestion, anterior rhinorrhea, loss of sense of

24 Rhinitis medicamentosa with nasal congestion appears readily reversible with suitabl

25 Uncontrolled asthma and nasal congestion are important, treatable risk factors f

26 ute for vaccinating infants, who may develop nasal congestion as a result of intranasal vaccination.I

27 asal spray (alpha adrenergic agonist) causes nasal congestion by rhinitis medicamentosa.

28 onist JNJ-39220675 relieved allergen-induced nasal congestion by using standard nasal symptom scoring

29 % difference; P = 0.02) but not with reduced nasal congestion compared with the control spray.

30 ptor antagonist, JNJ-39220675, in preventing nasal congestion induced by exposing participants with r

31 In patients with allergic rhinitis, nasal congestion is a risk factor for apnea and snoring.

32 Compared with all non-RSV-infected subjects, nasal congestion (odds ratio [OR], 2.0 [95% confidence i

33 Current smoking, stroke, epilepsy, and nasal congestion or upper respiratory tract infection we

34 Nasal congestion (OR 1.50), obesity (OR 1.54) and smokin

35 conjunctival injection, 58% rhinorrhoea, 54% nasal congestion, ptosis and facial flushing.

36 rs but can include red itchy eyes, sneezing, nasal congestion, rhinorrhea, coughing, bronchoconstrict

37 such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea, ptosis or eyelid oedema.

38 Significant improvement was observed in the nasal congestion score (P = 0.01) and sense of smell sco

39 , nasal airflow, nasal secretion weight, and nasal congestion scores.

40 tom scores for sore throat, nasal discharge, nasal congestion, sneezing, cough, scratchy throat, hoar

41 and colds (no fever, and >/=2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen

42 matic treatments for pain, fever, cough, and nasal congestion to use as needed.

43 nd placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV r

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。